These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

108 related items for PubMed ID: 116301

  • 1. Studies on some possible biochemical treatments of primary hyperoxaluria.
    Watts RW, Chalmers RA, Gibbs DA, Lawson AM, Purkiss P, Spellacy E.
    Q J Med; 1979 Apr; 48(190):259-72. PubMed ID: 116301
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Effect of dietary changes on urinary oxalate excretion and calcium oxalate supersaturation in patients with hyperoxaluric stone formation.
    Penniston KL, Nakada SY.
    Urology; 2009 Mar; 73(3):484-9. PubMed ID: 19118878
    [Abstract] [Full Text] [Related]

  • 4. [Pyridoxine can normalize oxaluria in idiopathic renal lithiasis].
    Jaeger P, Portmann L, Jacquet AF, Burckhardt P.
    Schweiz Med Wochenschr; 1986 Dec 13; 116(50):1783-6. PubMed ID: 3798070
    [Abstract] [Full Text] [Related]

  • 5. Oxalate metabolism in renal stone disease with special reference to calcium metabolism and intestinal absorption.
    Lindsjö M.
    Scand J Urol Nephrol Suppl; 1989 Dec 13; 119():1-53. PubMed ID: 2669121
    [Abstract] [Full Text] [Related]

  • 6. 'Enteral' hyperoxaluria. Effect of cholestyramine, calcium, neomycin, and bile acids on intestinal oxalate absorption in man.
    Caspary WF, Tönissen J, Lankisch PG.
    Acta Hepatogastroenterol (Stuttg); 1977 Jun 13; 24(3):193-200. PubMed ID: 883468
    [Abstract] [Full Text] [Related]

  • 7. Response to a physiologic dose of pyridoxine in type I primary hyperoxaluria.
    Yendt ER, Cohanim M.
    N Engl J Med; 1985 Apr 11; 312(15):953-7. PubMed ID: 3974685
    [Abstract] [Full Text] [Related]

  • 8. [Studies of urinary risk factors in urolithiasis].
    Ebisuno S, Kitagawa M, Morimoto S, Miyazaki Y, Minakata S, Yasukawa S, Fukatani T, Ohkawa T.
    Hinyokika Kiyo; 1985 Jan 11; 31(1):1-15. PubMed ID: 3993484
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Effect of pyridoxine supplementation on recurrent stone formers.
    Murthy MS, Farooqui S, Talwar HS, Thind SK, Nath R, Rajendran L, Bapna BC.
    Int J Clin Pharmacol Ther Toxicol; 1982 Sep 11; 20(9):434-7. PubMed ID: 7141762
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Effect of verapamil on urinary calcium and oxalate excretion in renal stone formers].
    Iguchi M, Ikegami M, Kiwamoto H, Umekawa T, Ishikawa Y, Kohri K, Kurita T.
    Hinyokika Kiyo; 1993 May 11; 39(5):425-31. PubMed ID: 8322624
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Effects of calcium, aluminium, magnesium and cholestyramine on hyperoxaluria in patients with jejunoileal bypass.
    Nordenvall B, Backman L, Larsson L, Tiselius HG.
    Acta Chir Scand; 1983 May 11; 149(1):93-8. PubMed ID: 6837229
    [Abstract] [Full Text] [Related]

  • 15. Hyperoxaluria in idiopathic calcium nephrolithiasis--what are the limits?
    Osther PJ.
    Scand J Urol Nephrol; 1999 Dec 11; 33(6):368-71. PubMed ID: 10636575
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [24-hour urinary oxalate excretion in healthy children and in children with calcium urolithiasis].
    Sikora P, Bieniaś B, Wawrzyszuk M, Zajaczkowska M.
    Pol Merkur Lekarski; 2008 Dec 11; 24 Suppl 4():76-9. PubMed ID: 18924510
    [Abstract] [Full Text] [Related]

  • 18. The effect of pyridoxine on oxalate dynamics in three cases of primary hyperoxaluria (with glycollic aciduria).
    Watts RW, Veall N, Purkiss P, Mansell MA, Haywood EF.
    Clin Sci (Lond); 1985 Jul 11; 69(1):87-90. PubMed ID: 4064559
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Absorptive hyperoxaluria leads to an increased risk for urolithiasis or nephrocalcinosis in cystic fibrosis.
    Hoppe B, von Unruh GE, Blank G, Rietschel E, Sidhu H, Laube N, Hesse A.
    Am J Kidney Dis; 2005 Sep 11; 46(3):440-5. PubMed ID: 16129205
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.